Further, it was reported that kynurenine and NAD+ salvage pathways play a critical role in the successful treatment of IBD, which suggests that potential drug targets include the hydroxycarboxylic acid receptor 3 (HCAR3), a low-affinity receptor for nicotinic acid, and NNMT [25]. Here, NNMT is linked to inflammatory bowel disease.